STOCK TITAN

Ironwood Pharmaceuticals, Inc. - - IRWD STOCK NEWS

Welcome to our dedicated page for Ironwood Pharmaceuticals - news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals - stock.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.

The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.

Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.

Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.

Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.

Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) has successfully completed the squeeze-out merger with VectivBio Holding AG, resulting in the cancellation and conversion of all remaining outstanding ordinary shares of VectivBio into the right to receive $17.00 per share in cash. The merger was approved by VectivBio shareholders at an extraordinary general meeting. Ironwood also completed a tender offer to purchase approximately 97.5 percent of outstanding shares, followed by the voluntary delisting of VectivBio shares from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
-
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The live webcast can be accessed through the Investors section of the company’s website. A replay will be available for 14 days following the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported 8% year-over-year growth in LINZESS® (Iinaclotide) EUTRx prescription demand, with U.S. net sales of $279 million, a 7% increase. Positive final data from STARS Nutrition for apraglutide in short bowel syndrome and colon-in-continuity was reported. Phase II study of CNP-104 in primary biliary cholangitis topline data expected in Q3 2024. Maintains Full Year 2023 Guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. will host its Q3 2023 investor update conference call on November 9, 2023. The call will be available for replay via telephone and the webcast will be archived on Ironwood's website for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences earnings
-
Rhea-AI Summary
Ironwood Pharmaceuticals presented new data at the ACG 2023 Annual Scientific Meeting and Postgraduate Course, highlighting the impact of linaclotide on symptoms of IBS-C and CIC and the burden of these disorders on patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
Rhea-AI Summary
Ironwood Pharmaceuticals presents findings showing linaclotide reduces use of rescue medications in children with functional constipation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.16%
Tags
-
Rhea-AI Summary
Ironwood Pharmaceuticals will host its second quarter 2023 investor update conference call and webcast on August 8, 2023. The call will be available for replay via telephone and the archived webcast will be available on Ironwood's website for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences earnings
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio Holding AG have successfully completed the tender offer for the outstanding ordinary shares of VectivBio. The tender offer was priced at $17.00 per share in cash, and approximately 97.60 percent of the outstanding shares were tendered. Ironwood intends to delist VectivBio's shares from Nasdaq and proceed with a squeeze-out merger under Swiss law.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none

FAQ

What is the current stock price of Ironwood Pharmaceuticals - (IRWD)?

The current stock price of Ironwood Pharmaceuticals - (IRWD) is $4.96 as of November 8, 2024.

What is the market cap of Ironwood Pharmaceuticals - (IRWD)?

The market cap of Ironwood Pharmaceuticals - (IRWD) is approximately 763.8M.

What does Ironwood Pharmaceuticals specialize in?

Ironwood Pharmaceuticals specializes in creating medicines for gastrointestinal disorders, focusing on conditions like IBS-C and CIC.

What is Ironwood's flagship product?

Ironwood's flagship product is a medicine for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

When was Ironwood Pharmaceuticals founded?

Ironwood Pharmaceuticals was founded in 1998.

What are some of Ironwood's recent achievements?

Recent achievements include advancing clinical trials, promising research data, and strategic partnerships to enhance product development and market reach.

How does Ironwood plan to expand its research and development capabilities?

Ironwood plans to expand through collaborative licenses, commercial agreements, and strategic acquisitions.

What areas does Ironwood's research pipeline target?

Ironwood's research pipeline targets both the upper and lower gastrointestinal tract.

What other conditions, besides IBS-C and CIC, is Ironwood working on?

Ironwood is also working on treatments for hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases.

How does Ironwood build value for its shareholders?

Ironwood builds value through achieving research milestones, strategic partnerships, and maintaining a strong product pipeline that attracts continued shareholder support.

Where is Ironwood Pharmaceuticals listed?

Ironwood Pharmaceuticals is listed on the NASDAQ under the symbol IRWD.

What is the company's mission?

Ironwood's mission is to create medicines that make a significant difference for patients, building value for shareholders, and empowering a passionate team.

Ironwood Pharmaceuticals, Inc. -

Nasdaq:IRWD

IRWD Rankings

IRWD Stock Data

763.79M
158.96M
1.69%
110.22%
7.47%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON